for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Galapagos NV

GLPG.O

Latest Trade

161.68USD

Change

0.00(0.00%)

Volume

76,141

Today's Range

161.63

 - 

163.11

52 Week Range

85.00

 - 

191.63

As of on the Euronext Amsterdam Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
161.68
Open
163.05
Volume
76,141
3M AVG Volume
7.73
Today's High
163.11
Today's Low
161.63
52 Week High
191.63
52 Week Low
85.00
Shares Out (MIL)
54.82
Market Cap (MIL)
9,085.53
Forward P/E
-31.07
Dividend (Yield %)
--

Next Event

Galapagos NV Extraordinary Shareholders Meeting

Latest Developments

更多

Hitgen Enters Into Dna-Encoded Library Based Drug Discovery Research Collaboration With Galapagos NV

Galapagos Increases Share Capital Through Warrant Exercises

Pharnext Updates On Collaboration with Galapagos

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Galapagos NV

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Industry

Biotechnology & Drugs

Contact Info

Generaal De Wittelaan 3

+32.15.342900

http://www.glpg.com

Executive Leadership

Onno van de Stolpe

Chairman of the Executive Committee, Chief Executive Officer, Executive Director

Rajesh B. Parekh

Non-Executive Chairman of the Board

Bart Filius

Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer

Piet Wigerinck

Member of the Executive Committee, Chief Scientific Officer

Walid Abi-Saab

Member of the Executive Committee, Chief Medical Officer

Key Stats

1.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.2K

2017

0.2K

2018

0.3K

2019(E)

0.2K
EPS (EUR)

2016

1.180

2017

-2.340

2018

-0.560

2019(E)

-4.720
Price To Earnings (TTM)
--
Price To Sales (TTM)
28.00
Price To Book (MRQ)
7.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.24
LT Debt To Equity (MRQ)
1.79
Return on Investment (TTM)
-6.22
Return on Equity (TTM)
-5.16

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up